RSS
Sanfilippo syndrome type B (or MPS-IIIB)
Orchard extends its collaboration with Manchester University to include MPS-IIIB
Orchard Therapeutics, a clinical-stage biotechnology company, has acquired an exclusive licence to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester. Read more
